leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals receives tax refund for Australian clinical study on Ifenprodil

The Canadian pharmaceutical firm is working on a Phase 2 trial in Australia for its lead drug Ifenprodil as a potential treatment for patients with a type of lung disease called idiopathic pulmonary fibrosis

Algernon Pharmaceuticals Inc. -
Vancouver-based Algernon said it plans to submit additional eligible expenses for reimbursement under the tax refund program

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) has received a refundable tax credit of around C$600,000 from its clinical research work in Australia.  

The Canadian pharmaceutical firm is working on a Phase 2 trial in Australia for its lead drug NP-120 drug (Ifenprodil) as a potential treatment for patients with a type of lung disease called idiopathic pulmonary fibrosis (IPF), which results in scarring of the lungs, and chronic cough. 

“Algernon’s unique business model of drug repurposing includes conducting as much clinical research as possible in Australia in order to take advantage of the Australian Government’s 41% refundable tax credit program,” said Christopher J Moreau, Algernon's CEO in a statement Monday.

READ: Algernon screens patients in Australia for Phase 2 Ifenprodil clinical study aimed at treating a type of lung disease and chronic cough

“This refund, while expected, is an important part of our capital-efficient R&D plan to drive value for our shareholders by keeping our research costs to an absolute minimum as we conduct early clinical investigations into the efficacy of our re-purposed compound targets.”

Vancouver-based Algernon said it plans to submit additional eligible expenses for reimbursement under the tax refund program.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Algernon Pharmaceuticals Inc.

Price: - -

CSE:AGN
Market: CSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals sees positive trending interim data from Phase 2b/3...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has received interim data from the Phase 2b part of their Phase 2b/3 clinical study of Ifenprodil for COVID-19. Moreau telling Proactive what the data showed...

on 15/12/20

2 min read